Phibro Animal Health - PAHC Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PAHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PAHC, but not buy additional shares or sell existing shares.
View PAHC analyst ratings or view top-rated stocks.

3 brokers have issued twelve-month price targets for Phibro Animal Health's stock. Their PAHC share price forecasts range from $17.00 to $19.00. On average, they expect the company's share price to reach $18.00 in the next year. This suggests a possible upside of 23.9% from the stock's current price.
View analysts price targets for PAHC or view top-rated stocks among Wall Street analysts.

Phibro Animal Health's stock was trading at $13.41 at the start of the year. Since then, PAHC shares have increased by 8.4% and is now trading at $14.53.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our PAHC earnings forecast.

Phibro Animal Health Co. (NASDAQ:PAHC) announced its quarterly earnings results on Wednesday, February, 8th. The company reported $0.34 EPS for the quarter, beating analysts' consensus estimates of $0.30 by $0.04. The business earned $244.60 million during the quarter, compared to the consensus estimate of $238.44 million. Phibro Animal Health had a trailing twelve-month return on equity of 18.90% and a net margin of 3.73%.

Phibro Animal Health declared a quarterly dividend on Monday, February 6th. Investors of record on Wednesday, March 1st will be given a dividend of $0.12 per share on Wednesday, March 22nd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 3.30%. The ex-dividend date is Tuesday, February 28th.
Read our dividend analysis for PAHC.

ETFs with the largest weight of Phibro Animal Health (NASDAQ:PAHC) stock in their portfolio include Invesco S&P SmallCap High Dividend Low Volatility ETF (XSHD), Invesco Nasdaq Future Gen 200 ETF (QQQS), First Trust Dow Jones Select Microcap Index Fund (FDM), Hartford Multifactor Small Cap ETF (ROSC), ETC 6 Meridian Low Beta Equity Strategy ETF (SIXL), Invesco S&P SmallCap 600 Pure Value ETF (RZV), Royce Quant Small-Cap Quality Value ETF (SQLV) and Invesco S&P SmallCap Health Care ETF (PSCH).

Phibro Animal Health (NASDAQ:PAHC) pays an annual dividend of $0.48 per share and currently has a dividend yield of 3.20%. The dividend payout ratio is 53.33%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PAHC will have a dividend payout ratio of 35.04% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PAHC.

Phibro Animal Health issued an update on its FY 2023 earnings guidance on Wednesday, February, 8th. The company provided earnings per share guidance of $1.21-$1.31 for the period, compared to the consensus EPS estimate of $1.20. The company issued revenue guidance of $960.00M-$1.00 billion, compared to the consensus revenue estimate of $982.11 million.

4 employees have rated Phibro Animal Health Chief Executive Officer Jack Bendheim on Glassdoor.com. Jack Bendheim has an approval rating of 100% among the company's employees. This puts Jack Bendheim in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Phibro Animal Health investors own include Zynga (ZNGA), Trevena (TRVN), Endo International (ENDP), Sonoma Pharmaceuticals (SNOA), Zynerba Pharmaceuticals (ZYNE), Intercept Pharmaceuticals (ICPT), VIVUS (VVUS), Zoetis (ZTS), Banco Bradesco (BBD) and Booking (BKNG).

Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."

Phibro Animal Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Pzena Investment Management LLC (4.86%), Heartland Advisors Inc. (1.76%), Renaissance Technologies LLC (1.31%), Dimensional Fund Advisors LP (1.28%), Smith Graham & Co. Investment Advisors LP (1.18%) and Morgan Stanley (1.15%). Insiders that own company stock include E Thomas Corcoran and Larry Lee Miller.
View institutional ownership trends.

Shares of PAHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PAHC stock can currently be purchased for approximately $14.53.

Phibro Animal Health (NASDAQ:PAHC) has a market capitalization of $588.52 million and generates $972.05 million in revenue each year. The company earns $49.17 million in net income (profit) each year or $0.90 on an earnings per share basis.

The company employs 1,860 workers across the globe.

Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The official website for the company is www.pahc.com. The company can be reached via phone at (201) 329-7300, via email at investor.relations@pahc.com, or via fax at 201-329-7399.